^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PT150

    i
    Other names: PT150, ORG34517, SCH-900636
    Associations

    News

    Trials
    Company:
    The Pop Test & Palisades Therap
    Drug class:
    Androgen receptor inhibitor, GCR antagonist
    Related drugs:
    Associations

    News

    Trials
    8ms
    PT150 Drug for Use in Alcohol Use Disorder (clinicaltrials.gov)
    P1, N=34, Recruiting, Pop Test Oncology LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PT150
    1year
    PT150 Drug for Use in Alcohol Use Disorder (clinicaltrials.gov)
    P1, N=34, Not yet recruiting, Pop Test Oncology LLC
    New P1 trial
    |
    PT150
    over5years
    [VIRTUAL] Pan-cancer analysis to identify a novel class of glucocorticoid and androgen receptor antagonists with potent anti-tumor activity. (ASCO 2020)
    In addition, both PT150 and PT157 significantly increased nab-paclitaxel sensitivity in nab-paclitaxel-resistant isogenic PDAC cells. Our work has identified previously undescribed mechanisms of oncogenesis in several cancer types, as well as an efficacious class of novel compounds with the potential to inhibit them. Research Funding: Palisades Therapeutics/Pop Test Oncology LLC
    Pan tumor
    |
    AR (Androgen receptor)
    |
    albumin-bound paclitaxel • PT150